Chang-Hee Min

Title: Chang-Hee Min: Innovator in Pharmaceutical Chemistry

Introduction

Chang-Hee Min is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that can inhibit caspase activity. His work has implications for treating various diseases associated with abnormal cell death.

Latest Patents

Chang-Hee Min holds a patent for an isoxazoline derivative and a process for its preparation. The patent describes an isoxazoline derivative of formula (I), along with its pharmaceutically acceptable salts, esters, and stereochemically isomeric forms. This invention is aimed at inhibiting the activity of caspases, which are crucial in the processes of inflammation and apoptosis. The pharmaceutical composition derived from this invention can be used to prevent diseases related to caspase activity, including dementia, cerebral stroke, AIDS, diabetes, gastric ulcers, and more.

Career Highlights

Chang-Hee Min is currently associated with LG Chem Investment Ltd., where he continues to innovate in the pharmaceutical sector. His research focuses on developing new therapeutic agents that can address critical health issues.

Collaborations

Chang-Hee Min has collaborated with notable colleagues, including Eunice Eun-Kyeong Kim and Mi-Jeong Park. These collaborations have further enhanced the research and development of pharmaceutical compounds.

Conclusion

Chang-Hee Min's contributions to pharmaceutical chemistry, particularly through his patent on isoxazoline derivatives, highlight his role as an innovator in the field. His work has the potential to significantly impact the treatment of various diseases.